Impact of inflammation on brain volume in multiple sclerosis

Archives of Neurology

Volumn 69, Issue 1, 2012, Pages 82-88

  Cheriyan, Jojy ^a   Kim, Soyeon ^a   Wolansky, Leo J ^a   Cook, Stuart D ^a   Cadavid, Diego ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GLATIRAMER; INTERFERON BETA SERINE;

AGE DISTRIBUTION; ARTICLE; BRAIN SIZE; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE ATROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROCESS MODEL; RELAPSE; SEX RATIO; SINGLE DRUG DOSE;

BRAIN; DISEASE PROGRESSION; ENCEPHALITIS; FEMALE; GADOLINIUM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PEPTIDES; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84862918455     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.674     Document Type: Article

References (37)

1. Whitwell JL. Longitudinal imaging: change and causality. Curr Opin Neurol. 2008; 21(4):410-416.
2. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68(22 suppl 3):22s-31s, discussion: 43s-54s.
3. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep. 2007;7(3):239-244. (Pubitemid 46831518)
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-269.
5. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L; Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53(8):1698-1704. (Pubitemid 29530342)
6. Simon JH, Jacobs LD, Campion MK, et al The Multiple Sclerosis Collaborative Research Group (MSCRG). A longitudinal study of brain atrophy in relapsingmultiple sclerosis. Neurology. 1999;53(1):139-148. (Pubitemid 29329662)
7. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology. 2000;55(11):1714-1718.
8. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis: European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000;123(pt 11):2256-2263.
9. Hardmeier M, Wagenpfeil S, Freitag P, et al; European IFN-1a in Relapsing MS Dose Comparison Trial Study Group. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology. 2005;64(2):236-240.
10. Miller DH, Soon D, Fernando KT, et al AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007; 68(17):1390-1401. (Pubitemid 46659091)
11. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008;71(2):136-144.
12. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IF-Nbeta- 1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-1983.
13. Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry. 2009;80 (12):1337-1343.
14. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFNbeta antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009; 73(18):1485-1492.
15. Festa ED, Hankiewicz K, Kim S, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009;15(11):1271-1279.
16. Shattuck DW, Leahy RM. BrainSuite: an automated cortical surface identification tool. Med Image Anal. 2002;6(2):129-142. (Pubitemid 35282822)
17. Cadavid D, Kim S, Peng B, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler. 2011;17(9):1113-1121.
18. Rice GP, Filippi M, Comi G; Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology. 2000;54(5):1145-1155. (Pubitemid 30151860)
19. Fazekas F, Sørensen PS, Filippi M, et al ESIMS. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler. 2005;11(4):433-440. (Pubitemid 40984238)
20. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon- beta1b in secondary progressive multiple sclerosis. Ann Neurol. 1999; 46(6):850-859.
21. Anderson VM, Bartlett JW, Fox NC, Fisniku L, Miller DH. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol. 2007;254(11):1588-1594. (Pubitemid 350159908)
22. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 months follow-up study. Eur J Neurol. 2001;8(1):37-42. (Pubitemid 32154572)
23. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; The European/Canadian Glatiramer Acetate Study Group. Short-term brain volume changes in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001;124(pt 9):1803-1812. (Pubitemid 32845441)
24. Raz N. The aging brain observed in vivo: differential changes and their modifiers. In: Cabeza R, Nyberg L, Park DC, eds. Cognitive Neuroscience of Aging: Linking Cognitive and Cerebral Aging. New York, New York: Oxford University Press; 2004: 17-55.
25. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59(9):1412-1420. (Pubitemid 35285996)
26. De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy in multiple sclerosis. J Neuroimaging. 2007;17(suppl 1):10s-15s. (Pubitemid 46558262)
27. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-285. (Pubitemid 28065253)
28. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
29. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
30. Zhao Y, Traboulsee A, Petkau A, Li D. Short-Term Changes in Gadolinium Enhancing Lesion Activity in Relapsing-Remitting Multiple Sclerosis: Implications for Clinical Trial Design. Madrid: ECTRIMS; 2006.
31. Di Filippo M, Anderson VM, Altmann DR, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2010;81(2):204-208.
32. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296-304. (Pubitemid 29416266)
33. Stevenson VL, Miller DH, Leary SM, et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68(6):713-718. (Pubitemid 30265270)
34. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain. 2005; 128(pt 6):1454-1460. (Pubitemid 40826197)
35. Hawker K, O'Connor P, Freedman MS, et al OLYMPUS Trial Group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized doubleblind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-471.
36. Furby J, Hayton T, Altmann D, et al. A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol. 2010;257(9):1508-1516.
37. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to longterm disability in multiple sclerosis. Ann Neurol. 2008;64(3):247-254.